INTRODUCTION
Composite tissue injuries present a compelling clinical challenge to both military and civilian trauma populations. Of the six million fractures that occur in the U. S. each year, approximately 10% are open fractures, which are characterized by concomitant soft tissue damage. These injuries experience a complication rate about twice that of closed fractures, with complications including infection, malunion, and non-union 1 . As a result, open fractures are often subject to multiple treatment strategies, repeated surgeries, and high direct and indirect costs 2 . Despite these multiple interventions, nearly two-thirds of patients remain significantly disabled long term (at seven years post-injury, and likely beyond) 3 .
One treatment strategy often employed in challenging bone healing scenarios is the delivery of bone morphogenetic protein-2 (BMP-2) on a collagen sponge. While most commonly used in cases of spinal fusion 4; 5 , BMP-2 has demonstrated clinical success in long bone fracture cases for over 15 years
However, BMP-2 has also been linked to side effects such heterotopic bone formation and inflammation 7 , both of which can be exacerbated by orthopaedic trauma 8 .
Segmental bone defect healing is known to exhibit a dose response to BMP-2 9 ; however, a minimally bridging dose for a segmental bone defect was unable to consistently bridge samesized bone defects in a composite bone and muscle defect model 10 . Thus, the effect of BMP-2 dose is of particular interest in traumatic composite defects.
The Gustilo classification system scores open fractures from class I-IIIC in terms of increasing severity. Assignment to broad classes I-III is determined by increasing size of soft tissue loss, but the hallmark of the most severe category IIIC is vascular damage -regardless of the degree of soft tissue damage 11 . The revascularization process is a rate-limiting step of the wound healing 12 and plays a crucial role in the clinical success of treatments for open fractures. Further, it is well established that angiogenesis and osteogenesis are linked 13 and that impaired revascularization impairs fracture healing in pre-clinical animal models 14 . Numerous therapeutic strategies targeting revascularization of bone have been employed, largely pre-clinically, including growth factor and cell delivery [15] [16] [17] [18] [19] .
One promising approach is the use of microvascular fragments (MVF), multicellular segments of mature vasculature that form angiogenic networks in vitro 20 . We have previously developed a pre-clinical small animal model of composite bone-muscle injury consisting of a critical size femoral defect with an overlying volumetric muscle loss 10 .
Our model recapitulates the clinical observation of impaired bone healing when concomitant soft tissue injury is present, and this has also been seen in similar pre-clinical models of composite tissue injury 10; 27-29 .
In this study, we tested the hypotheses that BMP-2-mediated functional regeneration of composite extremity injuries is dose dependent and can be further enhanced via co-delivery of adipose-derived microvascular fragments (MVF), which have been previously shown to increase tissue vascular volume.
METHODS

MVF Isolation and Construct Preparation
MVF were isolated as previously described 20 . Briefly, epididymal fat pads were harvested from Lewis rats, minced, and digested with a collagenase solution for 7 minutes at 37 °C. MVF were obtained through selective filtration to retain tissue between 50-500 µm. To prepare surgical constructs, MVF were suspended at a density of 80,000 MVF/mL in α MEM (ThermoFisher Scientific; Waltham, MA) along with BMP-2 (Pfizer, Inc.; New York, NY) and pipetted dropwise onto collagen sponges (5 mm diameter, 1 cm height; Kensey Nash/DSM; Exton, PA).
Viability of constructs cultured in α MEM with 10% fetal bovine serum (FBS; Atlanta Biologics; Atlanta, GA) and 1% penicillin-streptomycin-L-glutamine (ThermoFisher) was evaluated using a live/dead assay kit according to manufacturer's instructions (ThermoFisher). Cylindrical constructs were cut in half lengthwise to expose the center of the sponge, which was imaged.
Surgical Procedure
Unilateral composite defects were made in 13-week-old female Lewis rats (Charles River Laboratories; Wilmington, MA) by creating an internally stabilized 8 mm defect in the middiaphysis of the femur with an overlying 8 mm diameter full-thickness quadriceps defect as previously described 10 . Collagen sponges loaded with BMP-2 ± MVF were press fit into the defect. Sponges contained 2.5 µg BMP-2 without MVF (n=8 animals), 2.5 µg BMP-2 with MVF (n=8), 10 µg BMP-2 without MVF (n=9), or 10 µg BMP-2 with MVF (n=10). Animal number was determined from previous studies of segmental bone defect healing, and animals were randomly assigned to treatment groups. Animals were double-housed, maintained on a 12-hour 6 light/dark cycle, and allowed ad libitum access to food and water. At 12 weeks post-surgery, animals were euthanized by CO 2 inhalation. All animal experiments were performed in accordance with the Georgia Institute of Technology Institutional Animal Care and Use Committee (IACUC).
Bone Regeneration Analyses
Bone healing was qualitatively assessed by radiography at 2, 4, 8, and 12 weeks post-surgery and quantitatively assessed by micro-computed tomography (µCT) at 4, 8, and 12 weeks postsurgery. The defect region was scanned with a voxel size of 38.9 µm. The middle 6.5 mm of the defect was analyzed, and bone volume was quantified by Scanco software using a threshold corresponding to 50% of intact cortical bone 9; 10 .
Mechanical testing and histology were performed at the 12 week endpoint after euthanasia.
Thighs were harvested, soft tissue was cleared, and fixation plates were removed. Femur ends were potted in Wood's metal (Alfa Aesar) and tested in torsion at a rate of 3°/s to failure (ELF 3200, TA ElectroForce) 30 . Maximum torque (torque at failure) and torsional stiffness (linear region of torque vs. rotation) were calculated for all samples.
Following mechanical testing, one sample from each group was fixed in 10% neutral buffered formalin (NBF) for 24 hours and decalcified in a formic citrate solution (Newcomer Suppy, Inc;
Middleton, WI). Bone and muscle tissues were embedded in paraffin and sectioned at a thickness of 5 µm. Bone tissue was stained with hematoxylin and eosin (H&E); muscle tissue was stained with H&E and with Masson's Trichrome to observe fibrosis (Histotox Labs; Boulder, CO). Bone sections were also stained with rhodamine-labeled Griffonia simplicifolia lectin I (GS-1 lectin;
Vector Laboratories; Burlingame, CA) at a concentration of 10 µg/mL and counterstained with DAPI (ThermoFisher) diluted 1:1000 in phosphate buffered saline to identify blood vessels.
Serum Cytokine Quantification
At the week 12 endpoint, blood was collected via the rat tail vein from a subset of animals from each treatment group (n=5/group). Serum was collected from whole blood for multiplexed analyte analysis for 27 inflammatory cytokines and chemokines. Samples were prepared using a multiplexed rat cytokine/chemokine magnetic bead panel (MILLIPLEX RECYTMAG-65K), according to manufacturer's instructions. Data was collected using a MAGPIX multiplexing system (Luminex Corporation; Austin, TX).
Statistical Analysis
Data were analyzed using GraphPad Prism 7 and are represented as mean ± standard error of the mean (SEM). Bone volume, maximum torque, torsional stiffness, and cytokine levels were analyzed by two-way analysis of variance (ANOVA) and Bonferroni post-hoc tests with an alpha level of 0.05.
RESULTS
Construct Viability
MVF cultured in BMP-2 loaded collagen sponges maintained viability in vitro throughout the three-dimensional construct ( Figure 1 ). However, the multicellular MVF appeared to dissociate to single cells by day 3 of culture and reform networks by day 9-14.
Bone Regeneration
Radiography and µCT
Radiographs demonstrated that a majority of defects bridged in all four treatment groups ( Figure   2 ). By 12 weeks, all defects treated with 10 µg BMP-2, with and without MVF, had bridged (nine of nine and ten of ten, respectively). Seven of eight defects treated with 2.5 µg BMP-2 without MVF bridged, and five of eight defects treated with 2.5 µg BMP-2 with MVF bridged.
Bone volume in the defect region was measured by µCT and was significantly higher in the 10 µg dose groups than in the 2.5 µg dose groups ( Figure 3A ; overall effect, p=0.0312). There was no effect of the MVF treatment on bone volume and no significant interaction. The polar moment of inertia was also calculated as a measure of the distribution of bone relative to the central axis. pMOI was significantly lower in the 2.5 µg dose groups ( Figure 3B ; overall effect, p=0.0047). This corresponds to the more compact morphology observed in the radiographs ( Figure 2 ) and µCT reconstructions of the 2.5 µg dose groups ( Figure 3C ). Bone density was approximately 870 mm hydroxyapatite/cm 3 for all four groups.
Mechanics
The torque to failure was significantly higher for the 10 µg dose BMP-2 groups than the 2.5 µg dose groups (Figure 4 ; post hoc, p<0.001). There was no effect of MVF and no significant interaction. Despite the increased strength of the 10 µg BMP-2 treatment, the 10 µg dose without MVF group still only achieved 60.5% of intact strength. Stiffness was also significantly higher in the 10 µg dose groups than in the 2.5 µg dose groups (overall effect, p=0.0005), and stiffness was significantly decreased in groups with MVF compared to without MVF (overall effect, p=0.0098).
Histology
Qualitative histological assessment of bone defects supported the quantitative µCT data. The 10 µg dose without MVF group showed the greatest amount of bone organized in apparent lamellae, and both groups that received MVF showed larger areas of non-mineralized, marrow-like tissue ( Figure 5 ). There were no qualitative differences in relative number of lectin-stained blood vessel structures among treatment groups at the 12 week time point ( Figure 6 ). As expected, the untreated muscle defects did not heal over the course of this study. At the 12 week end point, muscle exhibited a large degree of fibrosis and fatty infiltration ( Figure 7 ). No qualitative differences in muscle healing were apparent between the well healing 10 µg BMP-2 without MVF and poorly healing 2.5 µg BMP-2 with MVF groups.
Serum Cytokine Quantification
Blood was collected at the 12 week end point to quantify systemic levels of circulating inflammatory cytokines (n=5/group). Levels of multiple interleukins (IL) were significantly decreased in blood samples taken from animals treated with the increased 10 µg BMP-2 dose groups, both with and without MVF (Figure 8 ). Both pro-inflammatory interleukins, such as IL1a and IL-1b, and anti-inflammatory interleukins, such as IL-5, IL-10, and IL-13, 31 were decreased in the 10 µg BMP-2 dose groups Pro-inflammatory eotaxin was also lower (p=0.0507) in the 10 µg BMP dose groups.
DISCUSSION
Composite tissue extremity injuries represent a significant challenge to orthopaedic surgeons and a momentous hardship for patients. Vascularization is an enabling step of wound healing, and we 1 0
hypothesized that BMP-2-mediated functional regeneration of composite extremity injuries would be dose dependent and could be further enhanced via co-delivery of adipose-derived microvascular fragments (MVF), which have been previously shown to increase tissue vascular volume.
BMP-2 is clinically approved for a number of bone healing indications and has shown success in treating long bone fractures and non-unions 6; 32 . There is a BMP-2 dose response in humans and in pre-clinical animal models, but precise dosing required for specific human applications is not well defined 9; 32 . High BMP-2 dosage has been linked a number of side effects including heterotopic ossification (HO) and increased inflammation 7 , and HO is also often increased in cases of trauma [33] [34] [35] . While a 2.5 µg dose of BMP-2 is a bridging dose in a segmental defect model 9 , it produces inconsistent bridging in this challenging composite defect model 10 . In this segmental defect model, HO has been observed at 30 µg doses of BMP-2 36; 37 . We showed in the present study that a 10 µg dose is sufficient to improve composite defect healing relative to the 2.5 µg dose and does not lead to mineralization outside the collagen sponge delivery vehicle. A moderately increased dose (e.g. 10 µg relative to 2.5 µg or 30 µg) may be required in composite injuries to compensate for the loss of endogenous stem and progenitor cells and growth factor availability as a result of the concomitant muscle loss. However, these studies together demonstrate the need for precise identification of the appropriate dosing window of BMP-2.
While muscle loss constitutes an increased level of trauma, this model does not incorporate head trauma or muscle crush, which are known contributors to human post traumatic HO 34; 35 .
Traumatically injured muscle can give rise to osteogenic progenitor cells 35 , but it is unknown whether a similar effect would be present in this model which cleanly removes a volumetric (Fig 3C) . Future studies to assess MVF retention, viability, and vascularization at earlier time points are required.
Beyond the vascular components of adipose-derived MVF, these structures also contain mesenchymal stem cells (MSCs) 26; 47 . Exogenously delivered adipose-derived MSCs have previously been shown to negatively affect mineralization when co-delivered with BMP-2 48 .
While BMP-2 upregulates osteogenic signaling of bone marrow-derived MSCs, adipose-derived 
